Seneste forsøg

EudraCT Number: 2022-000439-22

Sponsor Protocol Number: 67953964MDD3001_VENTURA-1

Start Date: 2023-01-25

Sponsor Name: Janssen-Cilag International NV

Full Title: A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...

Medical condition: Major Depressive Disorder (MDD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004873	10025453	Major depressive disorder NOS	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005947-58

Sponsor Protocol Number: M1095-PSA-201

Start Date: 2023-01-25

Sponsor Name: MoonLake Immunotherapeutics AG

Full Title: Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients with Active Psoriatic Arthritis

Medical condition: Active Psoriatic Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Ongoing) ES (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001484-27

Sponsor Protocol Number: NL67672.091.18

Start Date: 2023-01-24

Sponsor Name: radboudumc

Full Title: B cell Activation in Sjögren's Syndrome, Cutaneous Lupus Erythematodus and Systemic Sclerosis Tissues Analysis 2

Medical condition: Systemic Sclerosis Sjögren's Syndrome Cutaneous Lupus Erythematodus

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002924-11

Sponsor Protocol Number: LOLAbiome

Start Date: 2023-01-09

Sponsor Name: CBmed GmbH

Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis

Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004871	10024667	Liver cirrhosis	LLT
	20.0	100000004852	10014630	Encephalopathy hepatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003079-41

Sponsor Protocol Number: BOLD-100-001

Start Date: 2023-01-06

Sponsor Name: Bold Therapeutics, Inc. (Bold)

Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours

Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10052362	Metastatic colorectal cancer	LLT
	21.1	100000004864	10033605	Pancreatic cancer metastatic	LLT
	20.1	100000004864	10017770	Gastric carcinoma	LLT
	21.1	100000004864	10077846	Cholangiocarcinoma metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: IE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004931-10

Sponsor Protocol Number: R3918-PNH-2050

Start Date: 2023-01-04

Sponsor Name: Regeneron Pharmaceuticals, Inc.

Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria

Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH)

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	100000004857	10055629	Paroxysmal nocturnal hemoglobinuria	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GR (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001387-10

Sponsor Protocol Number: 220301

Start Date: 2022-12-29

Sponsor Name: TECNIMEDE, Sociedade Técnico-Medicinal, S.A.

Full Title: A Phase 3, Multicenter, Prospective, Placebo-Controlled, Randomized, Double-Blind Study to Assess the Efficacy and Safety of Favipiravir in Non-critical Hospitalized Patients with COVID-19 Pneumoni...

Medical condition: Coronavirus disease 2019 (COVID-19 pneumonia)

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.1	100000004862	10066740	Acute respiratory tract infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: PT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001685-35

Sponsor Protocol Number: ADT-2022-003

Start Date: 2022-12-27

Sponsor Name: Adeptio Pharmaceuticals Limited

Full Title: Randomized, double-blind, placebo controlled clinical trial of (+)-α-dihydrotetrabenazine in patients with moderate to severe tardive dyskinesia.

Medical condition: Tardive dyskinesia

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10029205 - Nervous system disorders	10043118	Tardive dyskinesia	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-000380-46

Sponsor Protocol Number: 75276617ALE1003

Start Date: 2022-12-27

Sponsor Name: Janssen-Cilag International NV

Full Title: A Phase I/Ib Study of JNJ-75276617 in Combination with Conventional Chemotherapy for Pediatric and Young Adult Participants with Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleo...

Medical condition: Relapsed/Refractory Acute Leukemias Harboring KMT2A, NPM1, or Nucleoporin Gene Alterations

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004864	10000844	Acute lymphoblastic leukaemia	LLT
	21.0	100000004864	10060354	Acute myeloblastic leukaemia	LLT
	21.0	100000004864	10000833	Acute leukaemia of unspecified cell type	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-001539-10

Sponsor Protocol Number: UX007-CL302

Start Date: 2022-12-27

Sponsor Name: Ultragenyx Pharmaceutical Inc.

Full Title: A Randomized, Double-blind, Multicenter Study to Determine the Effect of Triheptanoin Compared with Even-chain, Medium-chain Triglycerides (MCT) on Major Clinical Events (MCEs) in Pediatric Patient...

Medical condition: Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10077951	Fatty acid oxidation disorder	PT

Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing)

Trial results: (No results available)

Seneste forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner